What Changed This Week in FDA Cancer Approvals: How to Read the Page

Why this page exists

FDA keeps a running list of cancer drug approvals. News outlets turn each entry into a headline. The headline usually says a drug was approved for a cancer. The approval almost never says that.

This is a standing guide to reading those notices. What do the words mean? Which parts change care, and which do not?

Start with the indication, not the headline

An indication is the exact sentence in the label saying who the drug is for. It usually pins down five things at once:

• The cancer type. Often a named subtype, not just the organ.
• A biomarker: a lab feature the tumor must have.
• The treatment line. First treatment, or only after something else failed.
• Whether the drug is used alone or with named drugs.
• Sometimes an age group, or a limit such as "unresectable" or "metastatic."

Compare two claims. One: "approved for lung cancer." Two: "approved with chemotherapy, for adults with untreated metastatic non-small cell lung cancer whose tumors carry a certain protein." Only the second is the approval.

Traditional approval and accelerated approval are different promises

This distinction changes what an approval actually proves.

FDA created the accelerated approval pathway in 1992. It covers drugs for serious conditions with an unmet medical need. It lets FDA approve a drug on a surrogate endpoint. FDA defines that as a marker, such as a lab measurement or a scan. The marker is thought to predict benefit. It is not itself a measure of benefit.

FDA's own example is tumor shrinkage. It can approve a drug on evidence that tumors shrink, rather than waiting to learn whether people live longer. Shrinkage is considered reasonably likely to predict real benefit. The company must then run studies to confirm it.

Since 2012 it can also rest on an intermediate clinical endpoint. That is a measure of effect considered reasonably likely to predict benefit.

Traditional approval rests on clinical benefit itself. FDA describes that as an effect on how a patient survives, feels or functions.

The practical translation: accelerated approval is a bet with a deadline. Some confirmatory trials succeed. Some fail, and the indication is withdrawn.

Words that describe speed, not evidence

Several terms describe how fast FDA reviewed something. None of them says how well the drug works.

Priority review means FDA aims to act within 6 months instead of the standard 10. FDA says plainly that this does not change the standard for approval. It does not change the quality of evidence needed either.

Breakthrough therapy designation is granted when early clinical evidence suggests a drug may be a big improvement over what is available. It brings extra guidance during development. It is about promise, not about results.

What endpoint was measured

Three endpoints appear constantly, and they answer different questions.

Overall survival measures how long people lived. It is the hardest to move and the hardest to argue with.

Progression-free survival measures the time before scans show growth, or the person dies. It is faster to measure. It does not always mean living longer or feeling better.

Overall response rate is the share of people whose tumors shrank by a set amount. On its own it says nothing about how long that lasted. That is why it is usually paired with duration of response.

Our page on clinical trial phases explains where each of these usually appears in development.

Biomarkers and companion tests

Many modern approvals need a lab result before the drug can be used. When FDA approves a specific test alongside the drug, that test is called a companion diagnostic.

This part decides eligibility, so it is the part most likely to matter to a reader. A drug approved for tumors with a certain gene change is not available to someone whose tumor lacks it. The two cancers may look alike in every other way. Our page on biomarker testing covers how those results are produced.

Reading the harms alongside the benefit

Approval notices lead with efficacy. The label leads with safety, and it is the more useful document.

Look for a boxed warning. That is the strongest warning FDA applies. Look at the rate of grade 3 and 4 events, which are the severe ones. Then look at how many people stopped the drug because of a side effect. That number captures what was tolerable in practice.

Look at the trial population too. If the median age was 60 and everyone was fit, the safety profile describes that group.

Questions worth bringing to an appointment

• What exact indication was approved, and does my situation fall inside it?
• Does it require a biomarker, and has my tumor been tested for it?
• Was this accelerated or traditional approval, and if accelerated, what is the confirmatory trial measuring?
• What endpoint improved, and by how much in absolute terms?
• What are the common and the serious side effects, and how are they monitored?
• What does the schedule involve: infusions, tablets, clinic visits, blood tests?
• What does it cost, and is it covered?

Our pages on clinical trials versus standard treatment and targeted therapy go further.

What this story cannot tell

• It cannot tell whether any particular headline applies to a particular person.
• It cannot replace a treatment plan built by a care team who know the pathology report.
• It cannot show that one option is best for everyone. An approval compares a drug to one trial comparator, not to every alternative.
• It cannot support starting, stopping or changing treatment. That is a clinical decision.
• Labels change after approval, sometimes a lot. The current label is the one that governs.

Sources

• https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications
• https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/accelerated-approval
• https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review
• https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy
• https://www.fda.gov/medical-devices/in-vitro-diagnostics/companion-diagnostics

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

See an error, old source, or unclear wording? Tell us.